- Home
- PVLA vs EYPT Comparison
PVLA vs EYPT Comparison
Compare PVLA & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PVLA | EYPT |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 967.4M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | PVLA | EYPT |
|---|---|---|
| Price | $100.16 | $17.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $124.25 | $29.60 |
| AVG Volume (30 Days) | 258.4K | ★ 1.1M |
| Earning Date | 11-11-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.17 | $3.91 |
| 52 Week High | $106.71 | $17.82 |
Technical Indicators
Market Signals| Indicator | PVLA | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 74.48 |
| Support Level | $90.09 | $13.61 |
| Resistance Level | $106.71 | $14.96 |
| Average True Range (ATR) | 7.28 | 1.04 |
| MACD | -0.13 | 0.36 |
| Stochastic Oscillator | 75.95 | 99.43 |
Price Performance
Historical ComparisonAbout PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.